SAB Biotherapeutics (SABS) Other financing activities (2021 - 2026)

SAB Biotherapeutics (SABS) has 5 years of Other financing activities data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (changed N/A YoY) and the FY2024 annual result came in at $20409.0, down 99.97% from the prior year.
• Other financing activities grew to $3.0 million in Q1 2026, from -$3.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $59.6 million in Q4 2023 to a low of -$3.0 in Q4 2024.
• A 4-year average of $6.3 million and a median of $5130.0 in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities surged 5964968100.0% — and 2024, when it plunged 100.0%.
• Tracing SABS's Other financing activities over 4 years: stood at -$1.0 in 2022, then surged by 5964968100.0% to $59.6 million in 2023, then sank by 100.0% to -$3.0 in 2024, then soared by 99166766.67% to $3.0 million in 2026.
• The last three Other financing activities figures came in at $3.0 million (Q1 2026), -$3.0 (Q4 2024), and $20412.0 (Q1 2024), per Business Quant data.